Epilepsy is not inherently an autoimmune disorder, but an estimated 5 to 35% of new-onset seizure cases may have an autoimmune cause. In these cases, the immune system produces antibodies that attack proteins on the surface of brain cells, disrupting normal signaling and triggering seizures. This subset, often called autoimmune epilepsy, behaves very differently from other forms of the condition and typically responds better to immune-based treatments than to standard anti-seizure medications.
How Autoimmune Epilepsy Differs From Other Forms
Most epilepsy results from structural brain changes, genetic mutations, infections, or unknown causes. The immune system isn’t driving the seizures in those cases. In autoimmune epilepsy, the root problem is that your body’s immune defenses mistakenly target proteins that nerve cells need to function properly. This distinction matters because it changes how the condition is treated and how quickly it can progress.
The 2017 classification system from the International League Against Epilepsy organizes epilepsy into three diagnostic levels: seizure type, epilepsy type, and epilepsy syndrome. Within that framework, autoimmune epilepsy is recognized as its own category of cause, sitting alongside structural, genetic, infectious, and metabolic origins. It’s not a fringe diagnosis. It’s a formally recognized mechanism that neurologists actively screen for.
What Happens in the Brain
Several specific antibodies have been identified, each targeting a different protein on the surface of neurons. The three most well-studied are antibodies against the NMDA receptor, a protein called LGI1, and another called CASPR2. Each one disrupts brain signaling in a slightly different way, but the end result is the same: neurons become abnormally excitable and fire when they shouldn’t.
In the case of NMDA receptor antibodies, the immune attack causes neurons to pull the receptor inside the cell, effectively removing it from the surface. This reduces the brain’s ability to activate inhibitory neurons, the cells that normally keep electrical activity in check. Without that braking system, seizures and involuntary movements follow. This is why NMDA receptor autoimmune encephalitis often produces dramatic psychiatric symptoms alongside seizures, including hallucinations, behavioral changes, memory loss, and catatonia.
LGI1 antibodies work differently. LGI1 is a protein that connects two receptors across nerve cell junctions in the cortex and hippocampus. When antibodies disrupt this connection, the result is hyperexcitability that produces seizures, and when they cause the whole protein complex to be pulled inside the cell, memory impairment follows. Research in animal models has shown that these antibodies also block potassium channels, launching a cascade of changes in how neurons fire that directly produces the abnormal electrical patterns seen on brain scans.
Warning Signs That Point to an Autoimmune Cause
Autoimmune epilepsy often looks different from other epilepsy types at the start. Psychiatric symptoms are the most common early feature and are the presenting sign in about 60% of autoimmune encephalitis cases. Roughly one-third of patients are initially hospitalized on a psychiatric ward before the neurological cause is identified. This delay in diagnosis is a major problem because early treatment leads to better outcomes.
Clinicians use a system of “yellow flags” and “red flags” to identify when seizures might have an autoimmune origin. Yellow flags that should raise suspicion include rapid progression of psychosis that doesn’t respond to standard treatment, catatonia, drops in consciousness, abnormal involuntary movements (especially around the face and limbs), autonomic instability like sudden blood pressure or heart rate swings, and low sodium levels. Red flags that strongly warrant antibody testing include new-onset epileptic seizures alongside psychiatric symptoms, brief dystonic seizures affecting the face and arm, specific abnormalities on brain MRI or EEG, and signs of inflammation in spinal fluid without evidence of infection.
How It’s Diagnosed
Diagnosis relies on testing both blood and spinal fluid for antibodies. More than a dozen different antibodies have been linked to autoimmune epilepsy, so broad testing panels offer the best chance of catching the right one. Testing both samples simultaneously is recommended because some antibodies show up more clearly in one than the other.
The core laboratory technique involves exposing the patient’s blood serum and spinal fluid to specially engineered cells that display the target proteins on their surface. If antibodies are present, they bind to these cells and can be visualized under a microscope using fluorescent markers. Additional methods include testing for antibody binding on animal brain tissue and other specialized assays. All follow the same basic principle: detecting whether the patient’s immune system has produced antibodies that latch onto brain proteins.
The Cancer Connection
In some cases, autoimmune epilepsy is triggered by a tumor elsewhere in the body. This is called a paraneoplastic cause. The tumor produces proteins that resemble those found on brain cells, and when the immune system attacks the tumor, it also attacks the brain. Not every autoimmune epilepsy case involves cancer, but screening for tumors is a standard part of the workup.
The specific antibody found often points toward particular tumor types. NMDA receptor antibodies are associated with ovarian teratomas (a type of benign tumor). Antibodies against the GABA-B receptor are linked to small cell lung cancer. GABA-A receptor antibodies are associated with thymomas, tumors of the thymus gland in the chest. Other antibodies point toward testicular tumors, breast cancer, or lymphoma. When a tumor is found and removed, seizures often improve significantly because the immune trigger is eliminated.
Treatment Response
One of the most important distinctions of autoimmune epilepsy is that standard anti-seizure medications often don’t work well on their own. In a study of 50 patients with confirmed autoimmune epilepsy, 54% eventually became seizure-free. Of those, the majority (36% of all patients) achieved seizure freedom through immunotherapy, treatments that suppress or modulate the immune response. Only 10% responded to anti-seizure drugs alone.
The pattern was especially clear in patients with specific antibodies. Among those with antibodies targeting the potassium channel complex, 75% of those who became seizure-free did so with immunotherapy, while only 25% responded to anti-seizure drugs. This is why identifying the autoimmune cause matters so much: it redirects treatment toward the immune system rather than relying solely on medications designed to quiet electrical brain activity.
Long-Term Recovery and Cognitive Effects
Cognitive problems, particularly memory loss and difficulty with planning and decision-making, are common during autoimmune epilepsy and can persist even after seizures are controlled. Research on patients with LGI1 antibodies found that overall cognitive function improved significantly after immunotherapy, with scores on standard cognitive tests rising from 20 to 24 out of 30 over the course of treatment and follow-up. Executive function and delayed memory recall also showed meaningful gains.
Recovery isn’t always complete, though. Executive dysfunction, the ability to plan, organize, and shift between tasks, frequently persists as a long-term deficit even when other cognitive areas improve. Age plays a significant role in outcomes. Patients diagnosed at 65 or younger consistently scored better on cognitive tests both at diagnosis and at follow-up compared to older patients, even when both groups received immunotherapy on a similar timeline. Initial cognitive function at the time of diagnosis was also a strong predictor of long-term outcomes, reinforcing the importance of early detection and treatment.